A Novel Method Development and Validation by Ultra-Performance Liquid Chromatography for Assay of Asciminib in Dosage Form

Year 2023, Volume: 10 Issue: 2, 529 - 540, 31.05.2023

Pridhvi Krishna Gaddey Raja Sundararajan

https://doi.org/10.18596/jotcsa.1228364

Cited By: 1

Abstract

The main objective of the present study was to develop and validate simple, precise, sensitive and accurate UPLC method for the estimation of asciminib in pure and dosage form. The UPLC method was developed by using Waters Acquity liquid chromatographic system and Zorbax Phenyl (100x1.0mm,1.7µm) column. The developed method was validated according to the international conference on harmonization (ICH) guidelines. The chromatographic separation of asciminib with good resolutions has been achieved by using the mobile phase acetonitrile: ammonium dihydrogen phosphate buffer (20:80 v/v) at a flow rate of 0.5 mL/min, injection volume of 5 µL, and at 242 nm wavelength. The validated method was found to be linear in the range of 4 - 60 µg/mL. The limit of detection (LOD) and limit of quantification (LOQ) for asciminib were found to be 0.4 and 0.12 µg/mL respectively. The % RSD was found to be less than 2 % revealing the precision of the developed method. Besides, the recovery rate was observed close to 100 % confirming the accuracy of the method. Minor alterations in the chromatographic conditions have revealed robustness and ruggedness of the developed method. The developed analytical method is simple, precise, sensitive, and reproducible which can be used for the estimation of asciminib.

Keywords

UPLC, Asciminib, Buffer, Method development, Forced degradation studies

Supporting Institution

GITAM School of Pharmacy

Project Number

Not Applicable

Thanks

Nil

References

• 1. Patel M. Review Article: Chromatography Principle and Applications Mimansha. Int J Pharmacy&Pharmaceutical Res [Internet]. 2018;13(4):288–93.
• 2. Priyadarshini R, Raj GM, Gopal Shewade D. Chromatography – The Essence of Bioanalysis. Eur J Biomed Pharm Sci [Internet]. 2016;3(1):366–77.
• 3. Khan H, Ali J. UHPLC: Applications in Pharmaceutical Analysis. Asian J Pharm Anal [Internet]. 2017;7(2):124–31.
• 4. Sri RS, Sri KB, Mounika C. A Review on Comparative study of HPLC and UPLC. Res J Pharm Technol [Internet]. 2020;13(3):1570–4.
• 5. Srivastava B, Sharma BK, Baghel US, Yashwant, Sethi NK. Ultra Performance Liquid Chromatography (UPLC) : A Chromatography Technique. Int J Pharm Qual Assur [Internet]. 2010;2:19–25.
• 6. Chandarana C, Manani L, Patel V, Prajapati P. UPLC: A Prominent Analytical Technique For Pharmaceuticals. Int J Pharm Sci Rev Res [Internet]. 2016;37(2):192–201.
• 7. Roge AB, Firke SN, Dhane RM, Gunjkar VJ, Vadvalkar SM. Novel Achievement of HPLC: UPLC. Int J PharmTech Res [Internet]. 2011;3(3):1423–9.
• 8. Gumustas M, Kurbanoglu S, Uslu B, Ozkan SA. UPLC versus HPLC on Drug Analysis: Advantageous, Applications and Their Validation Parameters. Chromatographia [Internet]. 2013 Nov 27;76(21–22):1365–427.
• 9. Swartz ME, Murphy B. New Frontiers in Chromatography. Am Lab [Internet]. 2005 [cited 2023 May 13];22–7.
• 10. Breccia M, Colafigli G, Scalzulli E, Martelli M. Asciminib: An investigational agent for the treatment of chronic myeloid leukemia. Expert Opin Investig Drugs [Internet]. 2021 Aug 3;30(8):803–11.
• 11. Luna A, Pérez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuño C, et al. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia. Ann Hematol [Internet]. 2022 Oct 23;101(10):2263–70.
• 12. Cortes JE, Hochhaus A, Takahashi N, Larson RA, Issa GC, Bombaci F, et al. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase:Tthe ASC4FIRST phase III trial. Futur Oncol [Internet]. 2022 Dec;18(38):4161–70.
• 13. Hubbard WK. International Conference on Harmonisation; Guideline on the Validation of Analytical Procedures: Methodology; Availability. Fed Regist [Internet]. 1997;62(96):27464–7.